6th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia – Module - 3

This webcast is co-provided by the CancerNet, LLC and A. Webb Roberts Center for CME of Baylor Scott & White Health.

For more information visit: www.cancernetus.com/

Grantor: Amgen, Inc.; Merck Sharp & Dohme Corp.; AbbVie Inc.; Gilead Sciences Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Celgene; and Takeda/Millennium Pharmaceuticals, Inc.

Scroll to the Bottom of this Information to Begin this Course

Release date: July 28, 2017

Valid through: July 28, 2018

Specialty: Hematologists/Oncologists

Topic: Hematological Malignancies

Media: Internet

Estimated Time to Complete Activity: 130 minutes

Target Audience

This webcast is designed to meet the educational needs of hematologists/oncologists and other health care professionals who diagnose, treat, and manage patients with hematological malignancies such as Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia.

Statement of Need/Program Overview

This webcast is intended to improve care of patients with hematological malignancies such as Hodgkins lymphoma, B-cell lymphoma, multiple myeloma and leukemia by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with acute lymphoblastic leukemia
  • Evaluate the gene–gene co-occurrences and how compound genotypes are related to novel therapeutic options based clinical outcomes in patients with acute myeloid leukemia
  • Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of chronic myelogenous leukemia (CML)
  • Understand the time-based response milestones and monitoring in patients with CML

Credit Available

  • Physicians — maximum of 2.25 AMA PRA Category 1 Credits

All other healthcare professionals completing this course will be issued a statement of participation.

Faculty

Jorge Cortes, MD

Professor and Chair
Department of Leukemia
Division of Cancer Medicine
The University of Texas M D Anderson Cancer Center
Houston, TX

Elias Jabbour, MD

Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the co-providership of CancerNet, LLC and A. Webb Roberts Center for CME of Baylor Scott & White Health. The A. Webb Roberts Center for CME of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

Jorge Cortes, MD
  • Consultant: Ariad, Bristol-Myers Squibb, Pfizer, Novartis, Teva
  • Research Support: Ariad, Bristol-Myers Squibb, Pfizer, Novartis
Elias Jabbour, MD
  • Consultant: Bristol-Myers Squibb, Amgen, Takeda, Incyte, Pfizer

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:

  • Fredrick Hagemeister, MD, Advisory Board: Genentech, Gilead
  • Kamatham A. Naidu, PhD (CancerNet): No relevant financial relationships

All other individuals in a position to control content have no relevant financial relationships to disclose.

Hardware and Software Requirements

Recommends version 6.x browsers or higher from Microsoft or Netscape. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of content. These activities will be marked as such and will provide links to the required software. Required software may include:
Macromedia Flash
Apple QuickTime
Adobe Acrobat
Microsoft PowerPoint
Windows Media Player
RealNetworks RealOne Player
VLC Media Player

CME Provider Privacy Policy and Contact Information

A. Webb Roberts Center for CME of Baylor Scott & White Health observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support. To contact CME Provider, call 214-820-2317.

Course Viewing Requirements

Method of Participation and Request for Credit

There are no fees for participating and receiving CME credit for this webcast. During the period July 28, 2017 through July 28, 2018, participants must read all the material and study the educational webcast.

Instructions for Course Participation

This webcast includes text, graphics, and may include multimedia features. There are no fees for participating in or receiving credit for this webcast.

Click on all of the "medical education webcast" links and review the content presented. You must view all of the content to proceed to the post-test.

Read, complete, and submit answers to the post-test questions and evaluation questions online. You must answer all missed questions until you get them correct.

Participants must receive a test score of 100% in order to proceed to the course evaluation, and they must respond to all evaluation questions to receive a letter of credit.

If needed, you may save your answers and return to complete your course at a later date. You can find your saved course by selecting "Your Course History" on the left navigation bar. Then select "View" next to the course you would like to complete.

Letter of Credit & Transcripts

After submitting the webcast evaluation, you may access your letter of credit by selecting "Your Certificates" on the left navigation bar.

Select "Credit" to view letters of credit onscreen and print from your browser. You may print the letter of credit, but you may not alter the letter of credit.

Your credits will be tallied and may be viewed by selecting "View your transcripts" in the "Your Account" area.